tiprankstipranks
Trending News
More News >
Cantargia AB (DE:7V3)
FRANKFURT:7V3
Advertisement

Cantargia AB (7V3) Price & Analysis

Compare
2 Followers

7V3 Stock Chart & Stats

€0.26
>-€0.01(-1.59%)
At close: 4:00 PM EST
€0.26
>-€0.01(-1.59%)

Cantargia AB News

7V3 FAQ

What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was €0.06 and its highest was €0.35 in the past 12 months.
    What is Cantargia AB’s market cap?
    Cantargia AB’s market cap is €74.00M.
      When is Cantargia AB’s upcoming earnings report date?
      Cantargia AB’s upcoming earnings report date is Nov 19, 2025 which is in 10 days.
        How were Cantargia AB’s earnings last quarter?
        Cantargia AB released its earnings results on Aug 21, 2025. The company reported -€0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.015.
          Is Cantargia AB overvalued?
          According to Wall Street analysts Cantargia AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Cantargia AB pay dividends?
            Cantargia AB does not currently pay dividends.
            What is Cantargia AB’s EPS estimate?
            Cantargia AB’s EPS estimate is -0.02.
              How many shares outstanding does Cantargia AB have?
              Cantargia AB has 248,611,650 shares outstanding.
                What happened to Cantargia AB’s price movement after its last earnings report?
                Cantargia AB reported an EPS of -€0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.348%.
                  Which hedge fund is a major shareholder of Cantargia AB?
                  Currently, no hedge funds are holding shares in DE:7V3

                  Company Description

                  Cantargia AB

                  Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.

                  Cantargia AB (7V3) Earnings & Revenues

                  7V3 Stock 12 Month Forecast

                  Average Price Target

                  €1.27
                  ▲(388.46% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.2698,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.2698,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.2,0.28229230769230773,0.3645846153846154,0.44687692307692306,0.5291692307692308,0.6114615384615385,0.6937538461538462,0.7760461538461538,0.8583384615384615,0.9406307692307692,1.0229230769230768,1.1052153846153847,1.1875076923076924,{"y":1.2698,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.2,0.2823076923076923,0.3646153846153847,0.446923076923077,0.5292307692307693,0.6115384615384616,0.693846153846154,0.7761538461538462,0.8584615384615386,0.9407692307692308,1.0230769230769232,1.1053846153846154,1.1876923076923078,{"y":1.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.2,0.28229230769230773,0.3645846153846154,0.44687692307692306,0.5291692307692308,0.6114615384615385,0.6937538461538462,0.7760461538461538,0.8583384615384615,0.9406307692307692,1.0229230769230768,1.1052153846153847,1.1875076923076924,{"y":1.2698,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.24,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.14,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.11,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.11,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.09,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.25,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.22,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.2,"date":1759276800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Oncopeptides AB
                  SynAct Pharma AB
                  Xbrane Biopharma AB
                  Guard Therapeutics International AB
                  Immunicum AB
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis